{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:34:32Z","timestamp":1761561272495},"reference-count":9,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2008,9,4]],"date-time":"2008-09-04T00:00:00Z","timestamp":1220486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Current standards for establishing a cure of <jats:italic>H. pylori<\/jats:italic> infection require two breath tests taken at least 4 weeks apart, to be negative.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To determine the incremental cost and accuracy of repeating a urea breath test (UBT) in clinical practice.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We identified 419 patients with documented <jats:italic>Helicobacter pylori<\/jats:italic> infection who received eradication therapy and then had two breath tests, one 4\u2003weeks and the second at least 8\u2003weeks after the completion of treatment. <jats:italic>H.\u00a0pylori<\/jats:italic> infection was documented at baseline by a positive rapid urease test and histology.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In patients with successful eradication of <jats:italic>H.\u00a0pylori<\/jats:italic> infection (<jats:italic>n<\/jats:italic>\u2003=\u2003317), the mean\u2003\u00b1\u2003standard deviation delta over baseline (DOB) value before treatment was 43\u2003\u00b1\u200329\u2003ppm. Following treatment, the mean DOB in cured was 0.56\u2003\u00b1\u20032.1\u2003ppm at 1\u2003month and was similar to the value obtained at the second breath (0.68\u2003\u00b1\u20031; <jats:italic>P<\/jats:italic>\u2003=\u20030.39), which was performed 60\u2003\u00b1\u200371\u2003days after the first UBT. In patients remaining infected (<jats:italic>n<\/jats:italic>\u2003=\u2003102), the mean DOB at baseline was 47\u2003\u00b1\u200320\u2003ppm. Four weeks after treatment, the DOB was 40\u2003\u00b1\u200332\u2003ppm. The second UBT was performed 94\u2003\u00b1\u200372\u2003days after the first and the DOB was significantly greater than the first (47\u2003\u00b1\u200328; <jats:italic>P<\/jats:italic>\u2003=\u20030.040). There was no discordant result between the first breath test and second breath test. At a cost of 30\u2003euros\/breath test, the incremental cost of a second breath test was 12\u2003570\u2003euros in this cohort with no incremental clinical benefit.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> A single UBT, 4\u2003weeks after treatment is as effective as two serial breath tests in confirming <jats:italic>H.\u00a0pylori<\/jats:italic> eradication. The incremental cost of the second breath test is very high with no incremental clinical benefit.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2008.03846.x","type":"journal-article","created":{"date-parts":[[2008,9,4]],"date-time":"2008-09-04T13:52:17Z","timestamp":1220536337000},"page":"1304-1308","source":"Crossref","is-referenced-by-count":12,"title":["Duplicate breath testing to confirm eradication of <i>Helicobacter pylori<\/i>: incremental benefit and cost in 419 patients"],"prefix":"10.1111","volume":"28","author":[{"given":"N.","family":"VAKIL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"ZULLO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"RICCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"HASSAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"VAIRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,4]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Clinical Development and Labeling of Anti\u2010Infective Drug Products","author":"United States Food and Drug Administration"},{"key":"e_1_2_6_3_2","volume-title":"Guidance When Developing Therapeutic Regimens for the Eradication of Helicobacter pylori in GI diseases","author":"Health Canada"},{"key":"e_1_2_6_4_2","first-page":"S10","article-title":"Technical annex: tests used to assess Helicobacter pylori infection","volume":"41","author":"Working party of the European Helicobacter pylori Study Group","year":"1997","journal-title":"Gut"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200007000-00009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.50043.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02741.x"},{"key":"e_1_2_6_8_2","first-page":"101","article-title":"Levofloxacin\u2010based triple therapy for Helicobacter pylori retreatment: role of bacterial resistance","volume":"39","author":"Zullo A","year":"2007","journal-title":"Dig Liver Dis"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-8-200704170-00006"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.06.016"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2008.03846.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2008.03846.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T20:18:31Z","timestamp":1693513111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2008.03846.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,4]]},"references-count":9,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1365-2036.2008.03846.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03846.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,4]]}}}